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Introduction 
 
A key question in  developmental biology is how cells perceive and respond properly 
to their enviroment. Cells must not only sense and distinguish between stimuli, but 
also transduce the signal accurately, to activate the appropiate responses. Signal 
transduction is the process by which extracellular signals are detected and converted 
into intracellular signals, which, in turn, generate specific cellular responses. Signal 
transduction systems are typically arranged as networks of sequential protein kinases.  
 
Protein kinases 
 
The eukaryotic protein kinases make up a large superfamily of homologous proteins. 
They are related by virtue of their kinase domains (also known as catalytic domains), 
which consist of 250-300 amino acid residues. The kinase domains that define this 
group of enzymes contain 12 conserved subdomains that fold into a common 
catalytic core structure, as revealed by the 3-dimensional structures of several 
protein-serine kinases (Hanks et al 1995). 
There are many types of protein kinases involved in signal transduction. They all 
have same basic catalytic activity: they add a phosphate group to an amino acid in a 
target protein. The phosphate is provided  by hydrolyzing ATP to ADP. A protein 
kinase has an ATP-binding site and a catalytic center that can bind to the target amino 
acids. The phosphorylation of the target  protein changes its proprieties so that it turn 
acts to carry the signal transduction pathway to the next stage. 
Protein kinases can be classified both by the types of amino acids that they 
phosphorylate in the protein target and their location in the cell. 
Three groups of protein kinases are distinguished by the types of amino acid targets: 
 
• Protein serine/threonine kinases are responsible for the vast majority of 
phosphorylation vents in the cell. As their name indicates, they phosphorylate 
either serine or threonine in the target protein. 
  
• Protein tyrosine kinases phosphorylate tyrosine in the target protein. 
• Dual specificity kinases are less common and can phosphorilate target proteins 
on either tyrosine or serine/threonine. 
 
Protein kinases are found in two types of location: 
 
• Cytosolic protein kinases are most often Ser/Thr protein kinases. They are 
responsible for the vast majority of phosphorylation events in the cells. 
• Receptor protein kinase are found in the plasma membrane. They have a 
domain on the exterior of the cell that binds a ligand, and a catalytic domain 
within the cell that can act on a target protein. Most receptors with protein 
kinase activity are protein tyrosine kinases (RTK), although there are also 
some receptors of Ser/Thr kinase class. ( Hunter T., et al. 1987). 
 
Akt a serine/threonine kinase 
 
Akt protein was isolated as a gene product of the Akt gene. It’s a serine/threonine 
kinase with the plackstrin homology domain (PH) in its NH2 terminal region and 
catalytic domain closely related to protein kinase C (PKC) and protein kinase A 
(PKA) family members (Staal 1987).  
Mammalian genomes contain three widely expressed isoforms of Akt kinase. Tissue 
and organ expression of individual isoforms is shown in Fig 1. 
 
 
  
        
Figure 1: Akt expression profile 
 
Akt can be activated by a wide variety of growth stimuli such as growth factors and 
cytokines. The pathway of Akt activation is a process involving membrane 
traslocation and phosphorilation (Bellacosa et al, 1998). The typical route of Akt 
activation is mediated via tyrosine kinase receptors such as a receptors for insulin or 
certain growth factors. Upon stimulation, agonists activate receptor kinase function 
resulting in stimulation of tyrosyl phosphorilation of IRSs provides binding sites for 
specific proteins containing SH2 domains including the 85 kDa regulatory subunit of 
phospatidylinositol 3-kinase (PI3K), a crucial molecule in this signaling pathway. 
(Burgering and Coffer 1995). The plecstrin homology (PH) domain of PI3P triggers 
Akt traslocation to the plasma membrane (Bellacosa et al 1998). Furthermore, the 
increasing levels of phosphoinositides function as intracellular second-messenger 
molecules leading to activation of PI-dependent kinases (PDK1 and PDK2). PDKs 
activate Akt upon its membrane traslocation on threonine 308 (Thr 308) (Alessi et al 
1997) and serine 473 (Ser 473) (Bellacosa et al. 1998). Thr 308 phosphorilation is 
necessary for Akt activation, whereas Ser 473 phosphorilation is required as well as 
for maximal activity. (Downward 1998). Activated Akt becomes avaiable for 
phosphorilation of its downstream targets in various subcellular localizations and 
nucleus. Inactivation of Akt is accomplished by dephosphorylation by protein 
  
phosphatases such as protein phosphatase 2A, or by Akt antagonist (ceramides and 
PTEN) which blok an activation of this enzyme in certain steps  of its activation 
(Ozes et al. 2001). 
 
Figure 2: Akt downstream target molecules. Downstream target Akt substrates are grouped according to their function.  
 
Involvment of Akt in prosurvival and antiapoptotic mechanism 
 
This aspect of Akt physiology and pathophysiology is one of the most intensively 
studied with respect to its role in a number of areas of biomedical research spanning 
from oncology to cardiovascular medicine. Akt is critical for cell survival triggered 
by growth factors, extracellular matrix, and other stimuli. For example, the 
overexpression of wild type or activated Akt can rescue cells from apoptosis induced 
by various stress signals (Kauffmann-Zeh et al. 1997).  
Promotion of cell survival by Akt is accomplished on two levels. 
First, Akt is involved by trascriptional regulation of prosurvival and antiapoptotic 
genes. Akt promotes cell survival by directly phosphorylating trascription factors that 
  
control the expression of pro-and antiapoptotic genes. Akt appears to both negatively 
regulate factors that induce survival genes (Biggs et al 1999). 
Second, Akt promotes survival by direct phosphorilation of key regulators of  the 
apoptotic cascade. The most widely studied example of this type of regulation 
involves BAD, a membre of Bcl-2 family, whish promotes apoptosis by binding to 
and antagonizin the actions of prosurvival members of the family such as Bcl-2 and 
Bcl-XL. Akt can phosphorilate BAD and this modification promotes the 
sequestration of BAD in the cytosol, thus preventing BAD from interacting with Bcl-
2 or Bcl-XL (del Peso ey al. 1997). Akt has been shown to phosphorilate several 
trascription factors (CREB, NF-kB, Forkhead) many of which have been implicated 
in the expression of genes whose protein products regulate susceptibility to apoptosis 
(Barton et al. 1996). 
It appears that one or more factors may be involved in the regulation of FLIP, and 
studies to determine the role played by these factors in FLIP expression are currently 
under way. However, FLIP expression is critically dependent upon PI 3-kinase and 
Akt activity. These data add FLIP to the growing list of survival-related proteins 
reglated by the PI 3-kinase pathway (David J. Panka et al. 2000). 
 
C-FLIPL 
 
Cellular FLICE inhibitory protein (c-FLIP) is an endogenous inhibitor of death 
receptor-induced apoptosis throught the caspase 8 pathway, and is widely expressed 
in various tumors (Lee et al. 2003). C-FLIP acts as an inhibitor of apoptosis induced 
by various agents, including tumor necrosis factor (TNF), TNF-related apoptosis 
inducing ligand (TRAIL), T cell receptor (TCR), death receptor (DR) and Fas (Rippo 
et al. 2004). c-FLIP comes in two variants, c-FLIPS only contains two N-terminal 
DEDs very similar to the prodomains of caspase-8/-10. In contrast, the long splice 
form of c-FLIP (c-FLIPL) is identical in lenght with caspase-8, also contains N-
terminal tandem DEDS, but its caspase domain is altered, rendering it enzymically 
inactive. The 55 kDa FLIP (c-FLIPL) is expressed in many tissues. The most 
  
abundant expression of the protein is found in the heart, keletal muscle and kidney 
(Rasper D. Et al. 1998). The 25 kDa FLIP (c-FLIPS) is expressed in lymphatic tissues 
and its expression is dependent on the degree of cell activation (Imler M. Et al. 1997). 
c-FLIPL therefore has the classical structure of dominant-negative inhibitor: an intact 
upstream protein-protein interaction domain linked to an inactive downstream 
enzymic domain (Yeh, W.C. et al. 2000). Recently two reports demonstrated that c-
FLIPL is not only an inhibitor of apoptosis, but also an activator of procaspase-8, 
infact the caspase like-domain of c-FLIP, can activate the caspase-8 through 
heterodimerization (Chang et al. 2002). 
In addiction to the apoptosis inhibition, c-FLIPL mediate sthe activation of NF-kB and 
Erk by virtue of its capacity to recuirt the adaptor proteins involved in each signaling 
pathway, such as TRAF-1, TRAF-2, RIP and Raf-1 (Fang et al. 2004). The inhibition 
of JNK pathway by direct binding to MKK7 was also reported (Nakajima et al 2006). 
Homozygous distruption of c-FLIP gene in mice results in a failure of heart 
development at embryonic day 11.5, suggesting an essential role of cFLIP in cardiac 
development during embriogenesis (Yeh et al. 2000). 
 
GSK3β 
 
GSK3 was discovered  20 years ago as one of several protein kinases that 
phosphorylated and incativated glycogen synthase, the final enzyme in glycogen 
biosyntesis (Embi, N. et al . 1980). 
It was subsequently purified to homogeneity from skeletal muscle and molecular 
cloning revealed that there where two closely related isoforms, GSK3α and GSK3β, 
which are expressed ubiquitously in mammarian tissues ( Woodgett et al. 1990). The 
proteins share 97% sequence similarity within their kinase catalytic domains, but 
differ from one another outside this region, with GSK3α possessing an extended N-
terminal glycine-rich tail (Woodgett et al. 1991). 
The inhibition of GSK3 might underlie the insulin-induced dephosphorilation and 
activation of glycogen synthase (Cohen, P. 1978). We know that the inhibition of 
GSK3 by insulin results from its phosphorilation at an N-terminal serine residue 
  
(Ser21 in GSK3α and Ser9 in GSK3β) and it’s catalysed by protein kinase B (PKB; 
also called Akt)( Cross et al. 1995). In recent years, GSK3 has been implicated in the 
phosphorylation of many proteins and in the regulation os several cellular events 
(Cohen et. al 2001). In addiction, the same serine residue that is targeted by PKB/Akt 
is now known to be phosphorylated by other protein kinases in response to different 
signals. For example growth factor can inhibit GSK3 activity by means of the 
classical MAPK cascade (Parker et al. 1983).  
In 1992, many years after its initial identification, geneticist studing Drosophila 
melanogaster “rediscovered” GSK3 in a signalling pathway that is turned on by the 
secreted glycoprotein Wingless (Wnt). These findings implied that Wingless suppress 
GSK3 in this pathway (Siegfried et al. 1992). In particular, the pool of GSK3 that 
partecipates in WNT signalling is not free, but is present in a multiprotein complex 
that includes axin, β-catenin and the adenomatous polyposis coli (APC) protein ( 
Zeng et al.1997). In absence of WNT signal, GSK3 is active and phosphorylates axin, 
β-catenin and APC. This stabilizes axin and facilitates the interaction of APC with β-
catenin, but targets β-catenin for ubiquitin-mediated proteolytic destruction (Li. L. Et 
al. 1999).   
 
 
 
 
  
 
 
Figure 3: A proportion of GSK3 in cells is present in a multiprotein complex together with axin, the adenomatous 
polyposis coli (APC) protein and -catenin. In the absence of secreted glycoproteins, called WNTs, the GSK3 in this 
complex is active and phosphorylates axin, APC and -catenin. Axin is stabilized by phosphorylation, but 
phosphorylation of -catenin targets it for ubiquitylation and subsequent proteolytic destruction. The role of APC 
phosphorylation is less clear, but it seems to enhance its interaction with -catenin. After the binding of WNTs to their 
receptors, a signal-transduction pathway is triggered that has yet to be fully elucidated, but which seems to involve a 
protein, termed dishevelled (DVL), which, together with FRAT (frequently rearranged in advanced T-cell lymphomas), 
results in the displacement of axin (and hence APC and -catenin). This leads to the dephosphorylation of axin, APC 
and -catenin. The dephosphorylation of -catenin leads to its accumulation in cells and translocation to the nucleus, 
where it binds to members of the T-cell factor (TCF) family of transcription factors (also called LEF, for lymphoid-
enhancer factor), and stimulates the transcription of genes that are required for embryogenesis. The same pathway is 
likely to be involved in regulating the expression of other genes in adult tissues. 
   
GSK3β downregulation induced by the canonical WNT signal pathway and by the 
FGF-dependent  PI3K-AKT signaling pathway is independent of and dependent on 
Ser 9 phosphorilation, respectively (Frame et al. 2001). Because the mechanisms of  
GSK3β downregulation by WNT and FGF signaling are not the same, distinct 
GSK3β pools might be implicated in WNT and FGF signaling. Simultaneous 
activation of  WNT and FGF signaling pathway leads to the potentiation of the 
canonical WNT signaling pathway trought the promotion of the nuclear traslocation  
of β-catenin by the FGF-dependent PI3K-AKT signaling pathway. Therefore, 
coactivation of WNT and FGF signaling pathways during carcinogenesis leads to 
  
more malignant phenotypes due to the potentiation of β-catenin/TCF signaling 
cascades. 
 
 
 
 
 
Figure 4: Cross-talk of WNT and FGF signaling pathways. Schematic representation of the crosstalk of WNT and FGF 
signaling pathways during carcinogenesis. 
 
Receptor tyrosine kinases. 
Growth factors control cell growth, proliferation, differentiation, survival and 
migration by activating receptor tyrosine kinase (RTK) family members (Blume-
Jensen and Hunter, 2001). Signalling by RTKs requires ligand-induced receptor 
oligomerization, but evidences indicate that RTKs oligomerization per se is not 
always sufficient for kinase activation. There seems to be an additional requirement 
for ligand-induced conformational switches, ensuring that the catalytic domains are 
juxtaposed in a proper configuration to enable phosphorylation (Schlessinger, 2000; 
Jiang and Hunter, 1999). Anyway, upon ligand binding, cytoplasmic tyrosine residues 
of RTKs becomes autophosphorylated and thus provide docking sites for a variety of 
  
phosphotyrosine-binding proteins. The specific recruitment of these proteins, which 
harbour various, catalytic and scaffolding domains, determines the signalling output 
(Blume-Jensen and Hunter, 2001).  
Many RTKs, among which epidermial growth factor (EGFR) (Liebman, 2001), 
platelet-derived growth factor (PDGF) (Satoh et al., 1993; Nanberg and Westmark, 
1993) and RET (Chiariello e al., 1998) stimulate, through the small GTP-binding Ras, 
different MAP kinase pathways.  
 
MAP Kinases. 
 
Pathways involving MAP kinases are activated in response to an extraordinary 
diverse array of stimuli. These stimuli vary from growth factors and cytokines to 
irradiation, osmolarity, and shear stress of fluid flowing over a cell. These stimuli 
induce a specific dual phosphorylation on a conserved motif, Thr-Xaa-Tyr, present in 
all MAP kinases (Fig. 2). The best characterized substrates for MAP kinases are 
transcription factors. However, MAP kinases have the ability to phosphorylate many 
other proteins including other kinases, phospholipases, and cytoskeleton-associated 
proteins. 
In mammals, there are many MAP kinases with different biological functions, 
grouped  in distinctly regulated groups, of which the best known are ERK1/2 
(extracellular signal related kinase, ERK), JNKs (jun amino terminal kinase, JNK) 
and p38, which are involved in many cellular events such as proliferation, 
differentiation, apoptosis and stress (Chang and Karin, 2001) (Fig. 3). All MAP 
kinases recognize similiar phosphoacceptor sites composed of serine or threonine 
followed by a proline, and the amino acids that surround these sites further increase 
the specifity of recognition by the catalitic pocket of the enzyme. Full specificity is 
ensured through the interaction mediated by another site on the kinase that recognizes 
a distinct site on the substrate (docking site). Moerover, spatial localization of 
signalling molecules further auguments specificity in signal transduction (Roux and 
  
Bleins, 2004). Finally, cross-talk by scaffolding proteins regulate MAP kinase 
signaling beyond simple tethering (Chang and Karin, 2001; Qi and Elion, 2005). 
 
 
 
 
 
 
Figure 5 : MAPK pathway module. Core module of mitogen-activated protein kinase (MAPK) pathway is composed of 
three kinases. MAP kinase kinase kinase (MKKK), MAP kinase kinase (MKK), MAP kinase (MAPK), that are 
sequentially activated by phosphorylation. MAPKs are actibvated by dual phosphorylation of conserved threonine and 
tyrosine residues within the activation loop (TXY). 
 
 
  
 
Fig 6: Signaling cascade of the MAPK pathways. Schematic representation of signaling cascades leading to activation 
os MAP kinase to respective biological function 
 
 
Big “atypical” MAP kinases. 
 
The recently identified ERK5, ERK7 and ERK8 are significantly larger than the 
originally identified ERK1 and ERK2 due to an extended C-terminal domain. ERK5, 
also known as big mitogen-activated kinase 1 (BMK1) (Lee et al., 1995), is a 110 kDa 
protein, while ERK7 is 61 kDa protein and ERK8 is 60 kDa protein. All these MAP 
kinases are activated by dual phosphorylation on Thr-Xaa-Tyr motif. Recent 
information indicates that the C-terminal regions of ERK5 and ERK7 have important 
regulatory functions. The C-terminal region of ERK5 appears to regulate negatively 
its kinase activity (Zhou et al., 1995) and contains a putative bipartite nuclear 
  
translocation signal for ERK5 that functions in vivo following activation (Yan et al., 
2001). The C-terminal region of ERK5 also contains a myocyte enancher-binding 
factor 2-interacting region and a potent transcriptional activation domain (Kasler et 
al., 2000). Disruption of the gene encoding ERK5 led to angiogenic defects and 
embryonic lethality in mice (Yan et al., 2003) 
ERK7 is activated by autophosphorylation, which is regulated through its  C-terminal 
domain (Abe et al., 2001). Moreover,  the C-terminal region is required for the ability 
of ERK7 to localize to the nucleus and inhibit growth (Abe et al., 1999).  
ERK8 is the last identified member of the MAP kinase family (Abe et al., 2002). 
ERK8 represents the human orthologue of the rat ERK7 and is present in brain, 
kidney and lung. The overall amino acid identity of the human ERK8 and rat ERK7 
sequences is 69%. Comparison of the kinase domains reveals a sequence identity of 
about 82%, whereas the amino acid sequence identity of the C-terminal regions is 
only 53% (Abe et al., 2002). By contrast, sequence identity between other ERK 
orthologues is significantly higher.  
The possible physiological roles of ERK8 remain the less studied. The failure of 
ERK8 to phosphorylate many of tested substrates, c-jun, c-myc, histone H1, Ets-1, 
Elk-1 and paxillin has not elucitated its function. Its activation following stimulation 
by c-Src or cell exposure to serum hints at a function in response to mitogenic factors 
(Abe et al., 2002). Obviously, many possibilities remain to be explored when 
describing the function of ERK8. 
The objective of the present work is to determine the relevant MAP kinase family 
members involved in the signals from tyrosine kinase receptors to the nucleus. In 
particular, we examined the role of  JNK  in c-myc expression induced by PDGF and 
the activation c-Abl mediates RET/PTC3-dependent of the novel ERK8 MAP kinase. 
 
 
 
   
 
  
Materials and Methods 
  
Expression vectors. 
 
The expression vectors pCEFLP-SrcYF (constitutively active) and pCEFLP-SrcYF 
KM (dominant negative) were obtained by sub-cloning the corresponding cDNA 
obtained from pSM-SrcYF and pSM-SrcYF KM, kindly provided by H. Varmus 
(Chiariello et al., 2001). The HA-tagged form of Erk8 was generated by cloning the 
corresponding cDNA, kindly provided by M. Abe (Abe et al., 2002), in the pCEFL-
HA vector. The expression vector for the dominant negative Erk8 KR molecule was 
also provided by M. Abe (Abe et al., 2002). To generate the pCEFL-HA-Erk8 
expression vector, we amplified by PCR the corresponding cDNA using an 
“expressed sequence tag” (est) obtained from ResGen (Clone ID 5742965). This 
sequence data has been submitted to the GenBank database under accession number 
AY994058. The pCDNA3-Ptc3 expression plasmid has been previously described 
(Melillo et al., 2001). The Ptc3Y981, Ptc3Y1015, Ptc3Y1062, Ptc3 Kindead and Ptc3V804 
expression plasmid were generated by the QuikChangeTM Site-Directed Mutagenesis 
Kit (Stratagene), using pCDNA3-PTC3 as a template. Expression vectors for c-Abl 
and its oncogenic form, Bcr/Abl p210 (Bcr/Abl), have been previously described 
(Lobo et al., 2005; Sanchez-Prieto et al., 2002). The dominant negative c-Abl (Abl-
KD) expression vector was obtained by mutating a critical lysine in the kinase domain 
of c-Abl, contained in the pCEFL-AU5 vector. The c-myc and c-jun promoter 
reporter plasmids, pMyc-Luc and pJun-Luc, respectively, and the pCDNAIII-β-
galactosidase (β-gal) expression vector have been previously described (Chiariello et 
al., 2000; Chiariello et al., 2001). 
 
Reagents. 
 
The PP1 inhibitor was purchased from Biomol. All other chemicals were purchased 
from Sigma. 
  
 
Cell culture and transfections. 
 
293T cells and thyroid ARO cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 2mM L-
glutamine, and 100U/ml penicillin-streptomycin (Invitrogen). NIH3T3 fibroblasts 
were maintained in DMEM supplemented with 10% calf bovine serum (Bio 
Whittaker), 2mM L-glutamine, and 100U/ml penicillin-streptomycin (Invitrogen). 
293T and NIH3T3 cells were transfected by the LipofectAMINE reagent (Invitrogen), 
while ARO cells were transfected by the Lipofectamine 2000 reagent (Invitrogen), 
respectively, in accordance with the manufacturer’s instructions. For transfections, 
200 ng of HA-Erk8 and HA-Erk8δ and 100 ng of SrcYF, Abl Act.,  Bcr/Abl, 500 ng, 
1 µg and 2µg of FLIPL and of the different Ptc3 expression vectors were used, unless 
otherwise indicated. 
 
Antibodies. 
 
As primary antibodies rabbit polyclonal antibodies against Erk2 (C-14) and c-Src (N-
16) (Santa Cruz), phospho-MAPK (p42/p44) (Cell Signaling), GSK3β and phospho- 
GSK3β (Cell Signaling), c-FLIP (Abcam Corp.), β-catenin (Cell signaling), RET and 
phospho-RET (phospho-Tyr905) (Carlomagno et al., 2004); mouse monoclonal 
antibodies against  haemagglutinin (HA) epitopes (HA.11; Berkley Antibody 
Company, CA); c-Abl (BD Pharmingen) and to phospho-tyrosine; PY (Santa Cruz 
and Upstate Biotechnology); FLAG (Sigma); actine (Sigma), Akt (cell Signaling). 
 
 
Western blot analysis. 
 
Lysates of total cellular proteins or immunoprecipitates were analyzed by protein 
immunoblotting after SDS-PAGE with specific rabbit antisera or mouse monoclonal 
antibodies. Immunocomplexes were visualized by enhanced chemiluminescence 
  
detection (ECL or ECL Plus, Amersham-Pharmacia) with the use of goat antiserum to 
rabbit or mouse immunoglobulin G, coupled to horseradish peroxidase (Amersham-
Pharmacia). 
 
 
Reporter gene assays. 
 
ARO cells were transfected with different expression plasmids together with 20 ng of 
the pJLuc reporter plasmid. After 24 h incubation in serum-free media, the cells were 
lysed using reporter lysis buffer (Promega). Luciferase activity present in cellular 
lysates was assayed using D-luciferin and ATP as substrates, and light emission was 
quantitated using the 20n/20n luminometer as specified by the manufacturer (Turner 
BioSystems). 
 
 
In vitro kinase assay. 
 
Confluent plates of transfected NIH3T3 were kept  two hours (JNK assay) or 
overnight (MAPK assay) in serum-free medium. Cells were then washed with cold 
phosphate-buffered saline, and lysed at 4° C in a buffer containg 20 mM Hepes, pH 
7.5, 10 mM EGTA, 40 mM β-glycerophosphate, 1% IGEPAL, 2.5 mM MgCl2 , 1mM 
dithiothreitol, 2 mM sodium vanadate, 1mM phenylmathylsulfonyl fluoride, 20 µg/ml 
aprotinin, and 20 µg/ml leupeptin. Lysates were clarified by centrifugation at 12,000 
x g for 20 min at 4° C, and supernatants were incubated with 1 µg monoclonal 
antibody  against JNK (PharMingen) or with 1 µg polyclonal antibody against Erk2 
(C-14) (Santa Cruz), for 1 h at 4° C. Immunocomplexes were recovered with the aid 
of  protein A/G PLUS-Agarose (Santa Cruz Biotechnology). Pecipitates were washed 
three times with phosphate-buffered saline which contained 1% IGEPAL and 1mM 
vanadate, once with 100 mM Tris pH 7.5, 0.5 M LiCl, and once in kinase reaction 
buffer (12.5 mM MOPS, pH 7.5, 12.5 mM β-glycerophosphate, 7.5 mM MgCl2, 
  
0.5mM EGTA, 0.5 mM sodium fluoride, 0.5 mM vanadate).Assays were performed 
in a reaction buffer containing 1 µCi of [γ-32P]ATP, 20 µM ATP, 3mM dithiothreitol 
and 1 µg GST-ATF2 and myelin basic protein  (MBP, Sigma). After 30 min at 30°C, 
reactions were terminated by addition of  5X Laemli buffer. Samplers were heated at 
95°C for 5 min and analyzed by SDS-gel electrophoresis on 12% acrylamide gels. 
Autoradiography was performed with the aid of an intensifying screen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Study I 
 
Activation of the ERK8 MAP kinase by RET/PTC3, a constitutively active form of 
the RET proto-oncogene. 
 
RET is a typical trans-membrane receptor tyrosine-kinase (RTK), essential for the 
development of the sympathetic, parasympathetic and enteric nervous system and of the 
kidney (Schuchardt et al., 1994). In complex with four glycosylphosphatidylinositol 
(GPI)-anchored coreceptors, GFR-α 1–4, the RET protein binds growth factors of the 
glial-derived neurotrophic factor (GDNF) family, mediating their intracellular signaling 
(Airaksinen & Saarma, 2002). As for other RTKs, ligand interaction triggers 
autophosphorylation of different RET intracellular tyrosine residues that work as 
docking sites for several adaptor and effector signaling molecules (Santoro et al., 
2004). Among such tyrosines, while Tyr981 is a binding site for c-Src, Tyr1062 has been 
shown to mediate the interactions with most of RET effectors and to be responsible for 
activation of the Ras/Erk, PI3K/Akt, Jnk, p38 and Erk5 signaling pathways (Kurokawa 
et al., 2003). Finally, Tyr1015 is a recognized docking site for PLCγ (Borrello et al., 
1996). 
Gain-of-function mutations of RET have been repeatedly described in several human 
tumors (Pasini et al., 1996). RET germline point mutations are in fact responsible for 
the three clinical subtypes of the Multiple Endocrine Neoplasias type 2 (MEN2) 
syndrome, MEN2A, MEN2B and Familial Medullary Thyroid Carcinoma (FMTC) 
(Santoro et al., 2004). In addition, fusion of the intracellular kinase domain of RET with 
heterologous genes, caused by chromosomal inversions or translocations, generates the 
RET/PTC oncogenes, which represent the genetic hallmark of papillary thyroid 
carcinomas (PTC), accounting for more than 80-90% of all thyroid carcinomas 
(Sherman, 2003). Among the at least ten different RET/PTC rearrangements, 
RET/PTC1 and RET/PTC3, generated by the fusion with the H4 and RFG genes, 
respectively, are the most common types, accounting for more than 90% of all 
rearrangements (Nikiforov, 2002). 
 
 
  
Erk8 is activated by RET-dependent signaling pathway. 
 
We performed an in silico analysis of Erk8 gene expression in mouse tissues, through 
the public Mouse Gene Prediction Database resource (http://mgpd.med.utoronto.ca/) 
(Zhang et al., 2004). Among other tissues, Erk8 was expressed at very high levels in the 
thyroid, therefore suggesting a role for this kinase in signaling pathways involved in the 
homeostasis and/or pathology of this organ. As the RET/PTC oncogenes are frequently 
involved in human papillary thyroid carcinomas (Santoro et al., 2004), we decided to 
investigate their ability to modulate Erk8 activation. In particular, we investigated the 
role of RET/PTC3, a chimeric oncogene generated by the fusion of RET with the RFG 
gene (Fig. 7A) (Santoro et al., 1994).  
As an approach to score Erk8 activation, we used an anti-phospho-MAPK (Erk2) 
antibody that recognizes phosphorylation in the conserved MAP kinase TEY motif. We 
performed western blot analysis of 293T cells transfected with an HA epitope-tagged 
form of the Erk8 kinase, as previously described (Abe et al., 2002), and then 
distinguished the transfected HA-Erk8 and the endogenous Erk2 by their different 
molecular weights, ~60 kDa and ~45 kDa, respectively. As shown in figure 8B, 
RET/PTC3 overexpression readily induced Erk8 activation, at a level comparable to an 
activated form of c-Src (Src YF), used as a positive control (Abe et al., 2002). Of note, 
no signal in the ~60 kDa range was detected in the absence of HA-Erk8 transfection 
(Fig. 7B), indicating that the anti-phospho-MAPK antisera specifically recognized the 
Erk8 protein. As an additional control for the activity of RET/PTC3 and Src YF, both 
proteins activated the Erk2 MAP kinase (Fig. 7B), also scored by anti-phospho-MAPK 
western blot. Altogether, these results indicate that RET/PTC3 stimulates Erk8 activity. 
 
 
The Erk8 carboxy-terminal modulates activation of the MAP kinsase by 
RET/PTC3. 
 
While classical MAP kinases such as Erks, Jnks and p38s are only slightly larger than 
their minimum Ser/Thr kinase core, the atypical Erk5, Erk7 and Erk8 MAP kinases all 
  
contain long C-terminal domains whose functions are largely unknown. Yet, recent 
experiments performed on Erk5 (Buschbeck & Ullrich, 2005) and Erk7 (Abe et al., 
2001) have demonstrated a role for their C-terminal tail in the regulation of kinase 
intracellular localization and activity. Thus, we set up to investigate a role for the Erk8 
C-terminal domain in RET/PTC3-dependent activation of the kinase.  
The genomic organization of the Erk8 gene has been previously described (Abe et al., 
2002). By in silico analysis of available “expressed sequence tags” (est) clones we 
identified an Erk8 cDNA whose corresponding protein, when expressed, presented a 
molecular weight shorter (~35 kDa) than the described Erk8 protein (~60 kDa) (Fig. 
8A). We named this protein Erk8δ (accession # AY994058). Comparative analysis of 
the sequences for Erk8, Erk8δ and the Erk8 gene 
(http://www.ncbi.nlm.nih.gov/genome/guide/human/) revealed that Erk8δ corresponded 
to an alternatively spliced form of Erk8 in which an alternative exon 8 (exon 8a) 
contained a “stop” codon (Fig. 8B), therefore determining a 254-aminoacid long 
protein, lacking the Erk8 C-terminal domain (Fig. 8C). Thus, we took advantage of the 
availability of this naturally occurring C-terminally truncated protein, to evaluate the 
role of this domain in RET/PTC3-dependent Erk8 activation. As shown in figure 8D, 
RET/PTC3 was not able to induce Erk8δ activation while, as a control, it strongly 
activated Erk8. In the same experimental condition, Src YF, a described activator of 
Erk8 (Abe et al., 2002), also failed to stimulate Erk8δ activation (Fig. 8D), therefore 
establishing a key role for the C-terminal domain of Erk8 in the activation of this MAP 
kinase by various upstream stimuli. 
 
 
Tyrosine 981 of RET/PTC3 is necessary for Erk8 activation. 
 
Tyrosine phosphorylated residues in the kinase domain of RET, as well as of its 
derivate oncogenes, usually represent docking sites for adaptor proteins and enzymes 
that are able to propagate the signal to the intracellular environment (Santoro et al., 
2004). We therefore used RET/PTC3 molecules in which different tyrosine 
  
phosphorylation sites have been inactivated by mutating them to phenylalanines, to 
ascertain the dependency of RET/PTC3-induced Erk8 activation on the presence of 
these specific residues. Also, as these tyrosines have already been linked to the 
activation of different specific signaling pathways (Santoro et al., 2004), this approach 
could grant us the possibility to suggest the participation of some of these effectors in 
the modulation of Erk8 activity. In particular, tyrosine981 binds c-Src (Encinas et al., 
2004), tyrosine1015 is a docking site for PLCγ (Borrello et al., 1996) and tyrosine1062 is a 
multiple docking site that mediates most of RET signaling pathways (Kurokawa et al., 
2003), including Erk2 activation (Chiariello et al., 1998). 293T cells were transiently 
transfected with the HA-Erk8 molecule, together with RET/PTC3, RET/PTC3Y981, 
RET/PTC3Y1015 or RET/PTC3Y1062, respectively (numbers indicating RET/PTC3 
tyrosine residues correspond to their position in the wild-type RET receptor). 
Surprisingly, based on the observation that tyrosine1062 mediates most of RET signaling 
pathways (Kurokawa et al., 2003), the RET/PTC3Y1062 mutant activated Erk8 at an 
extent comparable to the RET/PTC3 molecule while, as expected (Chiariello et al., 
1998), this mutation strongly affected Erk2 activation (Fig. 9). The tyrosine1015 
mutation, involving a known binding site for PLCγ (Borrello et al., 1996), also did not 
affect Erk8 activation by RET/PTC3 (Fig. 9). Conversely, tyrosine981 mutation 
determined a dramatic reduction in RET/PTC3-dependent Erk8 activation, although 
resulting irrelevant to Erk2 activation (Fig. 10). As a control, RET/PTC3 Kindead, a 
kinase-inactive form of RET/PTC3 containing a mutation in the ATP-binding catalytic 
lysine (Lys758), was unable to activate both Erk8 and Erk2 (Fig. 9). These results 
therefore imply tyrosine981 of RET/PTC3 as a major site recognized by signaling 
molecules mediating RET/PTC3-dependent Erk8 activation. In addition, as tyrosine981 
has been previously recognized as a key residue for the binding of c-Src to RET 
(Encinas et al., 2004), they also suggest a role for c-Src in mediating RET/PTC3-
initiated signals impinging on Erk8 activation. 
 
 
 
  
Src activity is dispensable for RET/PTC3-dependent Erk8 activation 
 
Based on the above information and on the observation that c-Src activates Erk8 (Abe 
et al., 2002), we next sought to investigate if c-Src was able to mediate RET/PTC3-
dependent Erk8 activation. A classical approach to establish a role for Src kinases in 
cellular processes takes advantage of a pyrazolo-pyrimidine compound, PP1, which 
binds the ATP-binding pocket of these kinases therefore blocking their enzymatic 
activity (Hanke et al., 1996) and biological functions (Chiariello et al., 2001). Although 
PP1 has been described to affect RET kinase activity (in vitro IC50=100 nM) 
(Carlomagno et al., 2002), a specific mutation in valine804 in the RET kinase domain 
confers resistance (>50-fold increase of the IC50) to the compound (Carlomagno et al., 
2004). We, therefore, introduced such mutation in the RET/PTC3 kinase domain 
(RET/PTC3V804) rendering its activity significantly resistant to PP1, as scored by 
RET/PTC3V804 auto-phosphorylation and activation of Erk2 (Fig. 10A). As expected, 
kinase activity of the parental RET/PTC3 molecule was completely abolished at 
comparable concentrations (compare the 5-10 µM PP1 lanes) as evidenced by both 
RET/PTC3 auto-phosphorylation and activation of Erk2 (Fig. 10B). Surprisingly, while 
strongly inhibiting Src (data not shown), PP1 treatment of RET/PTC3V804-transfected 
cells only slightly affected Erk8 activity even at the highest doses tested (10 µM) (Fig. 
10C) and after extensive times of treatment (up to 10 hrs treatment, at 5 µM 
concentration) (Fig. 4D), thus excluding a role for c-Src and its related kinases (Hanke 
et al., 1996) in the control of RET/PTC3-induced Erk8 activation. As a complementary 
approach to ascertain the role of Src kinases in RET/PTC3 activation of Erk8, we also 
used a dominant negative form of c-Src, Src YF KM (Chiariello et al., 2001). As shown 
in figure 10E, overexpression of the dominant negative molecule did not affect Erk8 
activation while it effectively inhibited PDGF-induced activation of the c-myc promoter 
(Fig. 10F) (Chiariello et al., 2001). Altogether, these data clearly indicate that 
RET/PTC3 can use a Src-independent pathway to activate the Erk8 MAP kinase. 
 
 
  
c-Abl mediates RET/PTC3-dependent Erk8 activation. 
 
c-Abl, the cellular homologue of the Abelson murine leukemia virus, has been 
implicated in different cellular processes ranging from cell growth to survival, cellular 
stress, DNA-damage response and cell migration (Hantschel & Superti-Furga, 2004). 
From the structural point of view, c-Abl contains SH3, SH2 and tyrosine kinase 
domains whose arrangement and sequence very much resemble that of c-Src (Hantschel 
& Superti-Furga, 2004). These observations prompted us to investigate whether, 
similarly to Src, an activated form of c-Abl could induce Erk8 activation and, in turn, 
whether c-Abl could mediate RET/PTC3 activation of Erk8. As shown in figure 11A, 
an oncogenic, activated form of c-Abl, the Bcr/Abl fusion protein, readily induced Erk8 
activation, at a level comparable to an activated form of c-Src (Src YF), used as a 
positive control (Abe et al., 2002). Thus, we decided to investigate whether c-Abl is 
able to act as a link between RET/PTC3 and the stimulation of Erk8. As an approach, 
we used a kinase-defective, dominant negative form of c-Abl, Abl-KD. This dominant 
negative molecule strongly inhibited the RET/PTC3-dependent activation of Erk8 (Fig. 
11B), thus suggesting that c-Abl is a likely mediator in the pathway connecting 
RET/PTC3 to the activation of the Erk8 MAP kinase. 
To control a vast range of cellular processes, c-Abl interacts with a large variety of 
cellular proteins, including phosphatases, kinases, signaling adaptors, transcription 
factors, cytoskeletal proteins and cell cycle regulators (Hantschel & Superti-Furga, 
2004). To determine whether c-Abl can interact with Erk8 in vivo, 293T cells were 
transfected with HA-Erk8 and either wild-type c-Abl or the control vector, 
immunoprecipitated with an anti-HA antibody and then analized by western blot with 
an anti-abl antisera. As shown in figure 11C, c-Abl clearly co-immunoprecipitated with 
Erk8, therefore suggesting a role for physical interaction in the control of Erk8 
activation by c-Abl.  
We have previously shown that tyrosine981 in RET/PTC3 mediates RET/PTC3-
dependent Erk8 activation (Fig. 9), representing a major site recognized by signaling 
molecules intervening in such process. We therefore investigated whether the 
  
tyrosine981 residue was also able to mediate RET/PTC3 activation of c-Abl. Taking 
advantage of the observation that tyrosine phosphorylation of c-Abl correlates with its 
activation (Plattner et al., 1999), we cotransfected an autophosphorylation-impaired, 
AU5-tagged, c-Abl molecule, together with RET/PTC3, RET/PTC3Y981, 
RET/PTC3Y1015 or RET/PTC3Y1062, respectively, immunoprecipitated these samples by 
anti-AU5 antibodies and analyzed them by anti-phospho-tyrosine western blot. As 
show in figure 11D, RET/PTC3 clearly induced Abl phosphorylation. Importantly, 
RET/PTC3Y981 was strongly impaired in its ability to induce phosphorylation of the c-
Abl protein, as compared to RET/PTC3 (Fig. 11D). In the same experiment, 
RET/PTC3Y1062 and RET/PTC3Y1015 exerted more limited or no effects, as compared to 
RET/PTC3 (Fig. 11D). Ultimately, the RET/PTC3 Kindead was unable to induce c-Abl 
phosphorylation, establishing a requirement for RET/PTC3 kinase activity in c-Abl 
activation (Fig. 11D). Together, these results clearly indicate that RET/PTC3, through 
its tyrosine981, can utilize an Abl-dependent pathway to stimulate Erk8 activation. 
 
 
A kinase-defective mutant for Erk8 interferes with RET/PTC3 signaling. 
 
The expression of the c-jun proto-oncogene is rapidly and transiently induced by 
different growth factors and cellular oncogenes (Marinissen et al., 1999). Among them, 
an oncogenic rearrangement of the RET proto-oncogene is able to strongly induce c-jun 
expression (Ishizaka et al., 1991), therefore establishing this gene as part of RET 
signaling pathway. To investigate whether the RET/PTC3 oncogene was able to 
stimulate the activity of the c-jun promoter, we took advantage of the availability of a 
reporter plasmid carrying the luciferase gene under the control of the murine c-jun 
promoter (Chiariello et al., 2000; Marinissen et al., 1999). Cotransfection of thyroid 
ARO cells with this reporter plasmid and increasing concentrations of the RET/PTC3 
cDNA revealed that this oncogene could strongly induce the activity of the c-jun 
promoter (Fig. 12A). To evaluate whether Erk8 activation is involved in RET/PTC3 
signaling to the c-jun promoter, we next used a dominant negative, kinase defective 
(data not shown) Erk8 molecule. For these experiments, we therefore cotransfected 
  
RET/PTC3 with the c-jun reporter plasmid and increasing amounts of the Erk8 KR 
expression vector. As shown in figure 12B, the dominant negative Erk8 molecule 
caused a strong, although incomplete inhibition of RET/PTC3-dependent c-jun 
promoter stimulation, suggesting the existence of both Erk8-dependent and -
independent pathways linking RET/PTC3 to the expression of the c-jun proto-
oncogene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
  
Study 2 
 
Regulation of Akt activity by c-FLIPL . 
 
FLIPL interacts with Akt. 
 
Using a yeast two-hybrid screening, we identified new unreported Akt interactors. 
Dual-reporter gene activity identified 82 positive clones. A clone, the number 8, was 
been choose as a positive interactor with Akt and this clone was identified as the 
cellular FLIPL. All screenings were repeated in  triplicate. 
To confirm the interaction between Akt and FLIPL we performed a 
coimmunoprecipitation in vivo, between these two proteins. To this aim, Hela cells 
were transiently trasfected with two plasmids, Akt-HA and c-FLIPL-Flag. We 
trasfected Hela cells with Akt-HA only like a negative control. An anti-Flag antibody 
was used to immunoprecipitate Flag-FLIPL and than we blotted with an anti-HA 
antibody. The results confirmed the interaction between Akt and Flip; in the negative 
control we were not able to see any bands (Fig. 13). 
 
 
c-FLIP overexpression does not interfere with the expressions levels and 
phosphorylation of Akt. 
 
In order to understand the interaction between FLIPL and Akt, we tried to realize if 
the overexpression of FLIPL, in 293-cells, could in some way modify the expression 
or activity of Akt. The 293-cells were trasfected with c-FLIPL and stimulated for 15 
min.with insulin (10-6M)(infact insuline stimulates Akt activity).  
As a control, non trasfected 293-cells were utilized and stimulated with insulin for the 
same time and at the same concentrations. 
The results confirmed that the expression levels and Akt phosphorilation, after c-
FLIPL overexpression, in 293-cells, are unmodified. (Fig. 14) 
 
  
 
c-FlipL overexpression interferes with the levels of phosphorilation of GSK3B.  
 
From the data that we obtained by c-Flip overexpresion, we did not find any 
interference either with the endogenous levels of expression, or with the levels of 
phosphorylation of Akt, so we focused our studies on the possibility that c-FLIP  
could have an effect on the expression or on the activity of some Akt substrates. In 
order to do that, we trasfected, in transient, c-FLIPL in 293-cells and analyzed the 
total lysates by western blots for GSK3β (metabolic substrate of Akt) and Bad 
(involved in the intrinsic pathway of apoptosis). 
Astonishingly, the levels of phosphorylation of GSK3β in cells expressing high levels 
of  c-FLIPL were clearly reduced if compared to the control, whereas Bad expression  
levels remained unchanged. c-FLIPL overexpression in 293-cells influences the 
phosphorylation but not the expression levels of  endogenous GSK3β. (Fig 15-16) 
 
 
The overexpression of c-FLIPL influences the cellular localization of GSK3β. 
 
Besides having a role in the metabolism of glucose, GSk3β is also important in 
cellular proliferation. Infact, once migrated into the nucleus, it phosphorilates many 
transcriptional factors such as cyclin D1 and c-Jun (Diehl,J.A.et al. 1998). At this 
point of our study, we investigated if the c-FLIP overexpression, besides influencing 
the activity of GSK3, could also regulate its cellular localization. We made a 
separation between nucleus and cytoplasm in 293-cells trasfected in transient with c-
FLIPL. Cytoplasmatic and nuclear extracts were analyzed by Western Blot with an 
anti-GSK3β antibody. Interestingly the result showed that the overexpression of c-
FLIPL in 293-cells reduces the GSK3β levels in the nucleus preventing, the  
phosphorilation of some transcriptional factors.(Fig 17)                                                                      
                                        
  
 
  
c-FLIPL overexpression is inversely related  with β-catenin expression levels. 
  
As well as in the glucose metabolism, GSK3β is also responsible for the regulation of 
β-catenin degradation. The active form of GSK3β (dephosphorilated) links the β-
catenin with the axin protein in a compound, favouring the degradation by 
ubiquitination. The β-catenin if not degraded, moves into the nucleus and activates 
some transcriptional factors important for the proliferation and differentiation (Cohen 
et al. 2001). 
Considering these informations and that the c-FLIPL overexpression seems to reduce 
clearly the phosphorilation levels of GSK3β, we wondered if the levels of  
endogenous β-catenin were also reduced as a consequence of the activation of 
GSK3β. The results showed that in 293-cells with c-FLIPL  overexpession β-catenin 
levels were clearly reduced  if compared to the control. (Fig 18) 
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Figure 13: The amount of transfectd plasmids (pcDNA3-HA-Akt wt; D +, D-) as (CMV3xFlag -FlipL) is 5 µ g. The 
total lysates were immunoprecipitati ON A 4 °C using an antibody anti-Flag (Sigma) and then were added to the 
samples letting to hibridate the wheel at 4 °C for 1h with 20 µl of protein A/G plus (Santa Cruz). The immunoprecipitati 
were loaded on acrylamide gel to 10% and subjected to SDS page and then transferred to nitrocellulose filter. A 
quantity of lisati total (50 µ g) was analyzed to normalize the experiment. 
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Picture 14: 293-cells have been trasfected with CMV3xFlag-FlipL and treated with insulin (10-6 M). An amount of 
total lysates (5µg) have been loaded upon acrylamide-gel at 10% , exposed to SDS page,and later moved on a 
nitrocellulose-filter. The filter has been hybridized with anti-Akt and anti-P-Akt antibodies in order to evaluate the 
levels of expression and activities of Akt.       
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Fig. 15: Overexpression of c-FLIPL  in 293 cells induces a reduction of GSK3β in 293 cells, but not on the levels of 
expression of BAD. 
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Fig. 16:  293-cells have been cootrasfected with GSK3β and c-FLIPL and after 48 hours have been  
stimulated for 15 min with insulin (10¯6M) so as to start the pathway of Akt. The total extracts have been 
immunoprecipitated with an anti-Akt antibody and later analyzed via Western Blot with an anti-PGSK3β antibody. Also 
in this case the overexpression of c-FLIP induces to a remarkable reduction of both basal phosphorilation of GSK3β and 
of the phosphorilation induced by the insulinic stimulus, confirming the datum we previously obtained that is:the 
overexpression of c-FLIPL in 293-cells influences the phosphorolation of c-FLIPL in a negative way. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 17: C-FLIPL regulates the cellular compartimentation of GSK3β. 
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Picture 18: 293-cells trasfected with encreasing quantities of c-FLIPL. The bigger is the expression of c-FLIP,the 
smaller is the quantity of phosphorilated GSK3β; in this active form GSK3β regulates  the ubiquitination of β-catenin in 
a positive way. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Discussion 
 
The complexity of the mechanisms mediating intracellular signaling by RET and its 
activated forms, the RET/PTC and MEN2 oncogenes, has just begun to be appreciated. 
Indeed, the biological functions of these proteins result from the coordinated activity of 
multiple kinase cascades, whose integrated signals control renal development, 
histogenesis of the enteric nervous system and, possibly, tumor formation (Nikiforov, 
2002; Pasini et al., 1996; Santoro et al., 2004). In the first study, finding that 
RET/PTC3 activates Erk8 raises the possibility of a novel Erk8-dependent signaling 
pathway controlling RET biological functions. Interestingly, we have shown that Erk8 
activation depends on the integrity of tyrosine981, while tyrosine1062 mutation does not 
affect RET/PTC3-dependent activation of the kinase. This result clearly differentiates 
Erk8 from other MAP kinases already involved in RET signaling whose activation, on 
the contrary, strictly depends on RET tyrosine1062 (Hayashi et al., 2000).  
Although RET tyrosine981 has been previously recognized as a docking site for c-Src 
(Encinas et al., 2004) and this kinase modulates Erk8 activation (Abe et al., 2002), 
surprisingly, RET/PTC3 activation of Erk8 does not depend on c-Src. This result 
therefore suggests that additional molecules interact with tyrosine981 of RET/PTC3 and 
are responsible for the control of Erk8 activity. Indeed, in this report we present 
evidences that c-Abl controls RET/PTC3-dependent Erk8 activating phosphorylation 
(Fig. 14). As a corollary to this finding, for the first time we show that c-Abl is able to 
mediate RET-dependent signaling pathways. Not only RET/PTC3 induces c-Abl 
phosphorylation but such phenomenon also seems to be mediated by tyrosine981, in line 
with our observation that this tyrosine mediates Erk8 activation. These findings 
strongly support each other, especially considering that, up to now, the only known 
signaling molecule downstream of this tyrosine was c-Src, while most of the other RET 
effectors depended on the integrity of tyrosine1062.  
c-Abl as well as c-Src contain well characterized SH3 domains, with an high degree of 
conservation in terms of sequence identity and structure (Hantschel & Superti-Furga, 
2004). In c-Abl, this domain is important both for interaction with different proteins 
and for participation to an intramolecular regulatory mechanism (Wang, 2004). On the 
  
other hand, Erk8 contains two putative SH3-binding sites in its C-terminal tail (Abe et 
al., 2002). As the c-Src SH3 domain interacts in vitro with Erk8 (Abe et al., 2002) and 
we have demonstrated that c-Abl interacts in vivo with this MAP kinase, it is possible 
that this interaction is mediated by the c-Abl SH3 domain. This hypothesis is currently 
under investigation.  
The more recently identified Erk5, Erk7 and Erk8 molecules differentiate from classical 
MAP kinases (Erks, Jnks and p38s) in that they present long carboxy-terminal domains 
with no strong homology to other mammalian proteins. By using a naturally occurring 
Erk8 splice variant, Erk8δ, lacking the long carboxy-terminal domain, we show a key 
role for this domain in RET/PTC3-dependent activation. It is intriguing the possibility 
that distinct stimuli differently activate the Erk8 and Erk8δ proteins and, conversely, 
that Erk8δ may represent a modulator of Erk8 activation.  
Upon activation of different MAP kinases, a large number of transcription factors 
appears to control the expression of several growth promoting genes, such as c-jun and 
c-fos, and, through these, control a vast variety of cellular functions. Specifically, the c-
jun promoter has already been shown to represent a key site for the integration of 
signals coming from both cellular oncogenes (Chiariello et al., 2000) and extracellular 
ligands (Marinissen et al., 1999). It is therefore not surprising our observation that a 
dominant negative Erk8 molecule only partially inhibits the activation of the c-jun 
promoter. Indeed, we have previously demonstrated that signaling from RET impinges 
on the activation of at least another MAP kinase, Jnk (Chiariello et al., 1998), which is 
able to control the activity of the c-jun promoter (Marinissen et al., 1999). We can 
therefore expect Erk8 to be part of the complex network of kinases, whose activation 
ultimately determines the specific biological response to the activation of RET and its 
related oncogenes in different cellular environments. 
 
 
 
  
 
 
Figura 19 : Schematic rappresentation of the pathway connecting RET/PTC3 to the stimulation of ERK8 activation, 
throught tyrosine 981-dependent activation of c-Abl. 
TK, tyrosine kinase; RFG, RET Fused Gene. Numbers indicating RET/PTC3 tyrosine residues corrisponde to their 
position in the wild-type RET receptor. 
 
 
Cellular FLICE inhibitory protein (c-FLIP) is an endogenous inhibitor of death 
receptor-induced apoptosis throught the caspase 8 pathway, and is widely expressed 
in various tumors (Lee et al. 2003). 
Akt is a serine/threonine kinase with the plackstrin homology domain (PH) in its NH2 
terminal region and catalytic domain closely related to protein kinase C (PKC) and 
protein kinase A (PKA) family members (Staal 1987). However, FLIP expression is 
critically dependent upon PI3-kinase and Akt activity. (David J. Panka et al. 2000). 
The two-hybrid screening suggested that Akt and FLIPL interact.  We confirmed this 
interaction by coimmunoprecipitation in vivo of these two proteins. The interaction 
between FLIPL and Akt does not interfere either with the expression, or with the 
phosphorilation of Akt, but the overexpression of c-FLIPL interferes, instead, on the 
levels of phosphorilation of GSK3β, a substrate of Akt. 
  
GSK3β is one of several protein kinases that phosphorylated and inactivated 
glycogen synthase, the final enzyme in glycogen biosyntesis (Embi, N. et al . 1980). 
We know that the inhibition of GSK3 by insulin is dependent from its 
phosphorilation at an N-terminal serine residue (Ser21 in GSK3α and Ser9 in GSK3β) 
and this phosphorilation is catalysed by protein kinase B (PKB; also called 
Akt)(Cross et al. 1995). In recent years, GSK3β has been implicated in the 
phosphorylation of many proteins and in the regulation of several cellular events 
(Cohen et. al 2001). The activation of GSk3β activates the degradation-process of  β-
catenin (Fig.2) (Frame et al. 2001). We proved that the overexpression of c-FlipL  in 
Hela-cells determines a reduction of  GSK3β- phosphorilation even when this 
phosphorilation is induced by the insulinic stimulus through PI3K pathway. Thus, 
through the activation of GSK3β, c-FLIPL expression levels regulate β-catenin 
degradation.  
c-FLIPL and Akt interaction leads to a reduced phosphorilation of GSK3β (Akt 
substrate involved in the metabolism of glucose and cellular proliferation) by Akt and  
c-FLIPL overexpression in Hela-cells has also an effect on the cellular localization of 
GSK3β. Infact, the nuclear levels of this protein are drastically reduced when c-FlipL 
is overexpressed.In conclusion c-FLIPL protein is an Akt interactor and this 
interaction is responsible of the reduction of GSK3β phosphorilation levels  and β-
catenin cytoplamic levels. 
 
 
 
 
 
 
 
  
 
 
Figure 20: When c-FLIPL and Akt interact, the phosphorilation of GSK3β  decreases and, as a consequence, its 
activation takes place. The activation of GSK3β causes an increase of β-catenin degradation. 
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